Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Neuralstem to Begin Clinical Trial of Stem Cell Product in Beijing

publication date: Sep 28, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Neuralstem was granted SFDA approval to begin a clinical trial in China of its spinal cord stem cell product as a treatment for paralysis caused by ischemic stroke. A US company, Neuralstem’s China subsidiary (Suzhou Sun-Now Biopharmaceutical Co. Ltd.) will carry out the trial of NSI-566 at BaYi Brain Hospital in Beijing. More details....

Stock Symbol: (NYSE: CUR)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...